Announce At a Glance 20160212-2400

2016/2/20 Saturday < PGC Day >09:00 - 09:05
09:05 - 09:10
09:10 - 09:15
09:15 - 09:20
09:20 - 09:25
09:25 - 09:30
09:30 - 09:35
09:35 - 09:40
09:40 - 09:45
09:45 - 09:50
09:50 - 09:55
09:55 - 10:00
10:00 - 10:05
10:05 - 10:10
10:10 - 10:15
10:15 - 10:20
10:20 - 10:25
10:25 - 10:30
10:30 - 10:35
10:35 - 10:40
10:40 - 10:45
10:45 - 10:50
10:50 - 10:55
10:55 - 11:00
11:00 - 11:05
11:05 - 11:10
11:10 - 11:15
11:15 - 11:20
11:20 - 11:25
11:25 - 11:30
11:30 - 11:35
11:35 - 11:40
11:40 - 11:45
11:45 - 11:50
11:50 - 11:55
11:55 - 12:00
12:00 - 12:05
12:05 - 12:10
12:10 - 12:15
12:15 - 12:20
12:20 - 12:25
12:25 - 12:30
12:30 - 12:35
12:35 - 12:40
12:40 - 12:45
12:45 - 12:50
12:50 - 12:55
12:55 - 13:00
13:00 - 13:05
13:05 - 13:10
13:10 - 13:15
13:15 - 13:20
13:20 - 13:25
13:25 - 13:30
13:30 - 13:35
13:35 - 13:40
13:40 - 13:45
13:45 - 13:50
13:50 - 13:55
13:55 - 14:00
14:00 - 14:05
14:05 - 14:10
14:10 - 14:15
14:15 - 14:20
14:20 - 14:25
14:25 - 14:30
14:30 - 14:35
14:35 - 14:40
14:40 - 14:45
14:45 - 14:50
14:50 - 14:55
14:55 - 15:00
15:00 - 15:05
15:05 - 15:10
15:10 - 15:15
15:15 - 15:20
15:20 - 15:25
15:25 - 15:30
15:30 - 15:35
15:35 - 15:40
15:40 - 15:45
15:45 - 15:50
15:50 - 15:55
15:55 - 16:00
16:00 - 16:05
16:05 - 16:10
16:10 - 16:15
16:15 - 16:20
16:20 - 16:25
16:25 - 16:30
16:30 - 16:35
16:35 - 16:40
16:40 - 16:45
16:45 - 16:50
16:50 - 16:55
16:55 - 17:00
17:00 - 17:05
17:05 - 17:10
17:10 - 17:15
17:15 - 17:20

Room1A

Room 1D

Post Graduate Course A
What's New in the World?

Post Graduate Course B
What's New in Japan?

(Moderators: Fumio Imazeki, Yoshiyuki Ueno)
Virology of Hepatitis Virus
Takaji Wakita(Moderators: Diana Payawal, Gamal Shiha)
CT and MR Imaging for Diagnosis and Treatment of HCC
Takamichi Murakami

Chronic Hepatitis B Infection
George Lau

Pathology of Combined Carcinoma of the Liver
Fukuo Kondo

Coffee BreakCoffee Break(Moderators: Osamu Yokosuka, Naoya Sakamoto)Combination Therapy for HBV Treatment
Jinlin Hou(Moderators: A Kadir Dokmeci, Dong Jin Suh)
Local Treatment of HCC: RFA
Shuichiro Shiina

Gut Microbiota and Liver Disease
Jasmohan S. Bajaj

Conventional vs Beads TACE
Yasuaki Arai

Post Graduate Course C:"What will be Future for Industry" Beyond
Cure in HCV: Patient Reported Outcomes and Health Economics Zobair M.
Younossi (Sponsored by Gilead)

Retinoids in Liver Disease
Goshi Shiota

Lunch

Lunch

(Moderators: Norifumi Kawada, Hiroshi Yatsuhashi)
Molecular Spectra of HCC
Hiroyuki Aburatani(Moderators: Jinlin Hou , Laurentius A Lesmana)
HAIC for Advanced HCC
Shuntaro Obi

Liver Stem Cell and Carcinogenesis
Yock Young Dan

AIH What's New? (Pathology and Treatment AIH)
Atsushi Tanaka

Definition and Management of ALF/ACLF
Barjesh C. Sharma

miRNA and Liver Disease
Motoyuki Otsuka

Pathology and Treatment of PBC What's New?
Yogesh K. Chawla

Liver Pathology of PBC/PSC
Yasuni Nakanuma

Coffee BreakCoffee Break(Moderators: Namiki Izumi, Takafumi Ichida)
Hepatic Fibrosis
Ji Donｇ Jia(Moderators: Darrel Crawford, TBA)
Natural Course in HBV Infection
Masayuki Kurosaki

Imaging of Liver and Biliary Disease: CT/MRI
Necati Ormeci

Non-Invasive Assessment of Portal Hypertension Using
Doppler and Contrast-Enhanced US: What's New in Japan?
Hitoshi Maruyama

Imaging of Liver Disease: Elastography
Gamal Shiha

High Flow CHDF and OLCHDF
Ryuzo Abe

The Current Management of Gastric Varices and Portal
Hypertensive Gastropathy
Diana Payawal

Endoscopic Treatment of Cholangitis ERCP and POCS
Hiroyuki Isayama* The Program is subject to change.

2016/2/21 Sunday < HCV Day >Room 1 ABCD

Room 3

Room 4

Room 2F
5Opening Ceremony
Symposium 1 (Moderators: O. Yokosuka, J.L. Hou)Barriers of HCV Treatment in Asian PacificS1-1. Three Decades of Advances in Nucleotide Antivirals: From Research to Expanding AccessJohn C. Martin

S1-2. Barriers of HCV Treatment in Asia Pacific
Masao Omata
S1-3. Barriers of HCV Treatment in China
Lai Wei
S1-4. DAAs in Decompensated Cirrhosis
Shiv K. Sarin

Coffee BreakSymposium 2 (Moderators: M. Omata, G. Lau)
APASL Guideline in HCV Treatment
S2-1. New Therapies in HCV: Towards a Global Cure
Nezam Afdhal

S2-2. Treatment of HCV
Wan Long Chuang
S2-3. Genotype 4
Alaa Eldin Ibrahim
S2-4. Treatment of HCV Genotype 3 Infection in Asia-PacificWasim Jafri

Luncheon Symposium (Abbvie)

Luncheon
Symposium(Janssen)

Luncheon
Symposium(Sysmex)

Poster Viewing

09:00 - 09:05
09:05 - 09:10
09:10 - 09:15
09:15 - 09:20
09:20 - 09:25
09:25 - 09:30
09:30 - 09:35
09:35 - 09:40
09:40 - 09:45
09:45 - 09:50
09:50 - 09:55
09:55 - 10:00
10:00 - 10:05
10:05 - 10:10
10:10 - 10:15
10:15 - 10:20
10:20 - 10:25
10:25 - 10:30
10:30 - 10:35
10:35 - 10:40
10:40 - 10:45
10:45 - 10:50
10:50 - 10:55
10:55 - 11:00
11:00 - 11:05
11:05 - 11:10
11:10 - 11:15
11:15 - 11:20
11:20 - 11:25
11:25 - 11:30
11:30 - 11:35
11:35 - 11:40
11:40 - 11:45
11:45 - 11:50
11:50 - 11:55
11:55 - 12:00
12:00 - 12:05
12:05 - 12:10
12:10 - 12:15
12:15 - 12:20
12:20 - 12:25
12:25 - 12:30
12:30 - 12:35
12:35 - 12:40
12:40 - 12:45
12:45 - 12:50
12:50 - 12:55
12:55 - 13:00
13:00 - 13:05
13:05 - 13:10
13:10 - 13:15
13:15 - 13:20
13:20 - 13:25
13:25 - 13:30
13:30 - 13:35
13:35 - 13:40
13:40 - 13:45
13:45 - 13:50
13:50 - 13:55
13:55 - 14:00
14:00 - 14:05
14:05 - 14:10
14:10 - 14:15
14:15 - 14:20
14:20 - 14:25
14:25 - 14:30
14:30 - 14:35
14:35 - 14:40
14:40 - 14:45
14:45 - 14:50
14:50 - 14:55
14:55 - 15:00
15:00 - 15:05
15:05 - 15:10
15:10 - 15:15
15:15 - 15:20
15:20 - 15:25
15:25 - 15:30
15:30 - 15:35
15:35 - 15:40
15:40 - 15:45
15:45 - 15:50
15:50 - 15:55
15:55 - 16:00
16:00 - 16:05
16:05 - 16:10
16:10 - 16:15
16:15 - 16:20
16:20 - 16:25
16:25 - 16:30
16:30 - 16:35
16:35 - 16:40
16:40 - 16:45
16:45 - 16:50
16:50 - 16:55
16:55 - 17:00
17:00 - 17:05
17:05 - 17:10
17:10 - 17:15
17:15 - 17:20

Room 2

AIH-PBC Satellite Session(Moderators: M. Xiong, A.
Tanaka)Opening Remarks
Kwang-Hyub Han
Keynote Lecture
John Vierling
AIH in Asia Pacific
Masanori Abe
PBC in Asia-Pacific
Ma Xiong
AIH/PBC in Each Country/Region
Martin Weltman
Hong You
Deepak N. Amarapurkar
Osamu Yokosuka
Yoon Jun Kim

S2-5.Treatment in Developing Country
Salimur Rahman
S2-6. APASL HCV and Transplantation
Geoffrey McCaughan
S2-7. Management of HCV/HBV Co-Infection
George Lau
Symposium 3 (Moderators: E. Gane, J. Liang, H. Yatsuhashi)
HCV Treatment in Special Situation
S3-1. HCV Therapy-One Treatment for All Populations
Edward Gane

S3-2. Interferon-Free Treatment of Hepatitis C in Patients with Cirrohosis
before and after Transplant
Adrian Mike Di Bisceglie

Coffee BreakS3-3. Unmet Need for the Patients with Chronic Hepatitis C
Michael Manns

Symposium 4 (Moderators: L. Wei, A. Ibrahim,
N. Sakamoto)
Challenges in HCV Treatment
S4-1. Management on HCV/HIV Co-Infection
Cosmas Lesmana

Symposium 5 (Moderators: N. Ormeci, B.C.
Sharma, T. Takehara) Present Status of AntiHepatitis Therapy in Asian Pacific Region
S5-1. HCV Treatment in Philippines
Jose Sollano

S3-4 Clinical Outcomes of Anti Hepatitis C Therapy
Massimo Colombo

S4-2. Treatment in Co-Infection
Amarsanaa Jazag

S5-2.HCV in Turkey Current Statusand Future Action Plans
A. Kadir Dokmeci

S3-5. Challenges and Prospects of HCV Therapy Beyond the DAAs
T. Jake Liang

S4-3. DAA in Various Situation
Naoya Sakamoto

S5-3. HCV Treatment in Korea
Seung Woon Paik

S3-6. New Challenges in the "Post-Hepatitis" Era
Averell Sherker

S4-4. RAVs Determined by Ultradeep Sequencing
Hiroyuki Marusawa

S5-4. HCV Treatment in India
Barjesh C. Sharma

17:20-18:40

Poster Session

19:30 - 21:30

Welcome Reception* The Program is subject to change

AIH/PBC in Each Contry/Region
Zaigham Abbas
Diana A. Payawal
Ming-Ling Chang
Cumali Efe
Closing Remarks
Hajime Takikawa

Evening
Symposium(Sysmex)2016/2/22 Monday < HBV Day >Announce At a Glance 20160212-2400

Room 1BC

12:00 - 12:05
12:05 - 12:10
12:10 - 12:15
12:15 - 12:20
12:20 - 12:25
12:25 - 12:30
12:30 - 12:35
12:35 - 12:40
12:40 - 12:45
12:45 - 12:50
12:50 - 12:55
12:55 - 13:00
13:00 - 13:05
13:05 - 13:10
13:10 - 13:15
13:15 - 13:20
13:20 - 13:25
13:25 - 13:30
13:30 - 13:35
13:35 - 13:40
13:40 - 13:45
13:45 - 13:50
13:50 - 13:55
13:55 - 14:00
14:00 - 14:05
14:05 - 14:10
14:10 - 14:15
14:15 - 14:20
14:20 - 14:25
14:25 - 14:30
14:30 - 14:35
14:35 - 14:40
14:40 - 14:45
14:45 - 14:50
14:50 - 14:55
14:55 - 15:00
15:00 - 15:05
15:05 - 15:10
15:10 - 15:15
15:15 - 15:20
15:20 - 15:25
15:25 - 15:30
15:30 - 15:35
15:35 - 15:40
15:40 - 15:45
15:45 - 15:50
15:50 - 15:55
15:55 - 16:00
16:00 - 16:05
16:05 - 16:10
16:10 - 16:15
16:15 - 16:20
16:20 - 16:25
16:25 - 16:30
16:30 - 16:35
16:35 - 16:40
16:40 - 16:45
16:45 - 16:50
16:50 - 16:55
16:55 - 17:00
17:00 - 17:05
17:05 - 17:10
17:10 - 17:15
17:15 - 17:20
17:20 - 17:25
17:25 - 17:30
17:30 - 17:35
17:35 - 17:40

Room 1A

Room 1D

Room 2

Room 3Morning Symposium(Ajinomoto)

Morning Symposium(Abbott)

Session 1 (Moderators: A. Deepack, C. Lesmana, Y.
Ueno)
HBV Treatment in Various Countries 1
GS1-1. Nucleotide or IFN for the Treatment of HBV,(Prevention of HCC)
Deepak Amarapurkar

Session 2 (Moderators: B.C. Yoo, M. Sharma, H.
Gazinian)Significance of HBV Markers for Clinical Use GS2-1.
Pre-S Mutations of HBV and Hepatic Carcinogenesis
Byung-Chul Yoo

GS1-2. Clinical Profiles andTreatment Options of Chronic
Hepatitis B in Real-life Settings
Jinlin Hou

GS2-2. Approach for HBVTreatment
Manoj Sharma

GS3-2. ALF in EU
Richard Moreau HCV

GS1-3. HBV Treatment inJapan
Yoshiyuki Ueno

GS2-3. Cellular Hepatic
Immunology
Tatsuya Kanto

GS3-3. Artificial
Liver Support of
ALF
Kazuaki Inoue

Room 4

Room 5 Room 6 Room 7

Room 82
F

Presidential Lecture (Moderator: J.D. Jia)
Osamu Yokosuka
Presidential Plenary (Moderators: O. Yokosuka, L.A.
Lesmana, J. Sollano)PL-1. LDV/SOF+RBV in HCV Patients with Decompensated Cirrhosis or
Liver Transplantation: SOLAR-1+2
Edward Gane(10735)
PL-2 Sofosbuvir/Velpatasvir For The Treatment Of HCV DecompensatedLiver Disease Patients: ASTRAL-4 Study
Michael Charlton (10737)
PL-3 Serum HBV-RNA Levels Decline Significantly in Chronic Hepatitis
B Patients Dosed with REP2139-CA
Hendrik W. Reesink (10482 )PL-4192 Weeks Tenofovir Disoproxil Fumarate Monotherapy in ChinesePatients with Chronic Hepatitis B
Jinlin Hou (10365)
PL-5 Hepatocellular Carcinoma: Treatment Juntendo University
Radiofrequency Ablation (RFA) Training Program
Shuichiro Shiina (11141)
PL-6 Acute on Chronic Liver Failure AARC-ACLF Score Predicts 30
Day Survival better than CLIF-SOFA and MELD Scores in Patients with
ACLF

Session 3 (Moderators: M.
Mahtab, R. Mareau, S.
Mochida)Recent Progress in ALF
GS3-1. ALF in ASIA
Satoshi Mochida

HCV
HCV
HCV

HCV
HCV
HCV

GS1-4. HBV Treatment
in Philippines
Ian Homer Cua

HCV
HCV
HCV

Coffee BreakLecture 1 (Moderator: D.J. Suh)
Hepatitis B Treatment
Anna S. Lok

Session 1 (Moderators: H. Ozkan, A.
Chutaputti, I. Cua)HBV Treatment in Various Countries 2
GS1-5. HBV Treatment in Thailand
Anuchit Chutaputti

Session 4 (Moderators: A. Thompson, R. Gish, Transplantation
T. Kanto)
Treatment Towards HBsAg Clearance
Transplantation
GS4-1. New Insight of HBsAg Seroclearance
Jun Cheng

Lecture 2 (Moderator: J.H. Kao)
Hepatitis B in EU
Patrick Marcellin

GS1-6. HBV Treatment inIndonesia
Laurentius A. Lesmana

GS4-2. New Endpoints in HBVDrug Development
Robert G. Gish

Lecture 3 (Moderator: A.K. Dokmeci) Serum HBsAg and AFP
Levels during Acute Hepatitis Flare of Chronic Hepatitis B: A
New Look in the Natural Course and Antiviral Therapy Yun Fan
Liaw

GS1-7. HBV Treatment inTurkeyHasan Ozkan

Transplantation

Transplantation

Transplantation

GS4-3. ”Curing HBV-New Therapeutic
Approaches”
Alexander Thompson

Transplantation

10324
O-190
10690
O-191
10653
O-192
10683
O-193
10694
O-194
11324
O-195

HCV
HCV
HCV
HCV
HCV

10331
O-1
10844
O-2
10484
O-3
11100
O-4
11125
O-5
10670
O-6
11097
O-7
11072
O-8
10729
O-9
10726
O-10

HBV

10868
O-11
10740
O-12
10941
O-13
10517
O-14
10525
O-15

HBV

11000
O-196
10466
O-197
10223
O-198
10724
O-16
10731
O-17
10739
O-18
10971
O-19
10312
O-20
11231
O-21
20157
LBO-1
20160
LBO-2

HBV

HBV
HBV
HBV
HBV
HBV
HBV
HBV
HBV
HBV

HBV
HBV
HBV
HBV

10763
O-88
10680
O-89
11111
O-90
10780
O-91
10221
O-92
10260
O-93
10628
O-94
10693
O-95
10577
O-96
10961
O-97

11307
O-98
10506
O-99
10828
O-100
10799
O-101
10490
O-102

HCV 10121 HBV 10615 HCV
O-108
O-22
HCV 10132 HBV 10809 HCV
O-109
O-23
HCV 10285 HBV 10176 HCV
O-110
O-24
HCV 10692 HBV 11263 HCV
O-111
O-25
HCV 10725 HBV 10360 HCV
O-112
O-26
HCV 10727 HBV 10467 HCV
O-113
O-27
HCV 10877 HBV 10085
O-114
O-28
HCV 11034 HBV 11248
O-115
O-29
HCV 10805
O-72

20107
LBO-24

20082
LBO-2520061
LBO-2620155
LBO-2720122
LBO-2820111
LBO-29ACL
F
WS

HCV 10667 HBV 10225 Immune 11347
O-116
O-36
O-83
HCV 10736 HBV 10875 Immune 11272
O-117
O-31
O-84
HCV 10538 HBV 10418 Immune 10612
O-118
O-32
O-85
HCV 11099 HBV 10715 Immune 11003
O-119
O-33
O-86
HCV 10886 HBV 10935 Immune 10970
O-120
O-34
O-87
HCV 10580 HBV 11169
O-121
O-35
HCV 10915 HBV 11212
O-122
O-30

Luncheon Symposium(Gilead)Luncheon Symposium(Abbvie)

Luncheon Symposium(BMS)

Symposium 6 (Moderators: F.S. Wang , A. Lok, M. Mizokami)
Novel Therapeutic Strategies for HBV
S6-1. Chimeric Animal Model

Session 1 (Moderators: O. Baatakun, S.
Rahman, S. Hamid)
HBV Treatment in Various Countries 3
GS1-8. HBV Treatment in Korea
Jung Il Lee

Session 5 (Moderators: P. Marcellin, C.M.
Kim, T. Kanda)
Basis for Hepatitis Treatment
GS5-1. Various Hepatitis in Japan
Hiroshi Yatsuhashi

S6-2. Curing Chronic Hepatitis B Depends on the Restorationof Integrative Immunity against HBVFu-Sheng Wang

GS1-9. HBV Treatment inPakistan
Shahab Abid

GS5-2. HAV and HEV
Shigeo Nagashima

S6-3. Innate Immunity in Hepatitis B
Stephen Locarnini

GS1-10. HBV Treatment in
Mongolia
Oidov Baatarkuu

GS5-3. Treatment of HDV
Saeed Hamid

S6-4. HLA and HBV Infection
Masashi Mizokami

GS1-11. HBV Treatment in
Bangladesh
Salimur Rahman

GS5-4. Androgen Receptor andHepatitis Virus
Tatsuo Kanda

Symposium 7 (Moderators: J.D. Jia, J.H. Kao, F. Imazeki)
Treatment of HBV for a Cure
S7-1. Conventional Treatment
Jidong Jia

GS1-12. HBV Treatment in
Egypt
Gamal Shiha

GS5-5. Expression of mRNA in
Hepatitis B and C
Masao Honda

S7-2. Nucleotide
George Lau

GS1-13. HBV Treatment in USA:AASLD Guidelines 2015 and beyond
Robert G. Gish

GS5-6. Treatment of HEV
Zaigham Abbas

S7-3. Hepatitis B Towards Cure of Virus and Liver
DiseaseJia-Horng Kao

Symposium 8 (Moderators: F. Hollinger,
M.F. Yuen, Y. Tanaka)
Reactivation and Occult Infection of HBV
S8-1. Coinfection with HIV
Marion Peters

Session 6 (Moderators: J. George, T. Wakita,
N. Kato)Nobel Approach for Viral Research
GS6-1. Micro RNA and HCV
Takasuke Fukuhara

S7-4. Clinical Cure of Chronic Hepatitis B: Dream orReality
Fumitaka Suzuki

S8-2. HBV Reactivation(Insight of Integration)
Yasuhito Tanaka

GS6-2. GWAS
Koichi Matsuda

S7-5. Interferon Sequencing Therapy of HBVQin Ning

S8-3. Clinical Implication ofOccult Hepatitis B
Man-Fung Yuen

GS6-3. HBV/HCC MICA
Naoya Kato

S7-6. Update in Immunomodulator Therapy of Chronic
Hepatitis B
Teerha Piratvisuth

S8-4. Occult HBV
F. Blaine Hollinger

GS6-4. HCV Biology in the
FutureTakaji Wakita

Transplantation

ACLF Working
Party MTG
Transplantation
DILI / ALF
Harshad Devarbhavi
Transplantation

Sepsis / ACLF
Ashok Choudhury HCVHepatic
Encephalopathy
R K Dhiman

HCV
HCV

Acute Kidney Injury
HCV
Rakhi Maiwall
PortalHypertension
Shahab Abid
Artificial Liver
SupportRichard Moreau

HCV
HCV
HCV
HCV

Coffee BreakS7-7. Hepato-Renal Synd
Yogesh K. Chawla

17:40-19:00*The Program is subject to change.

HCV
HCV
HCV

GS6-5 IL28
Jacob George

Poster Session

HCV

20161
LBO-3
20124
LBO-4
20158
LBO-5
20159
LBO-6

Pediatric 11192
O-274
Pediatric 10479
O-275
Pediatric 10106
O-276
Pregnancy 11308
O-277
Pregnancy 10657
O-278
Pediatric 20005
LBO-21

11066 HCV 11142 HBV 11200 Basic 11007
O-123
O-207
O-103
O-37
10981 HCV 10672 HBV 11288 Basic 11041
O-124
O-208
O-104
O-38
HBV
10810 HCV 10523 HBV 11174 Basic 10195
O-125
O-209
O-39
O-105
HBV
10579 HCV 10673 HBV 11339 Basic 11011
O-126
O-210
O-106
O-40
HBV
10989 HCV 11252 HBV 10542 Basic 11362
O-127
O-211
O-107
O-41
HBV
20003 HCV 10387 HBV 11344 Basic 10083
O-128
O-212
LBO-7
O-42
HBV
20116 HCV 10684 HBV 10478 Basic 10237
O-129
O-213
LBO-8
O-43
HBV
20171 HCV 10882 HBV 11090 Basic 10325
O-130
O-214
LBO-9
O-44
HBV
20071 HCV 11063 HCC 10382 Basic 10428
O-141
O-215
LBO-10O-45
HBV
20110 HCV 10676 HCC 11171 Basic 11254
O-142
O-216
LBO-11O-46
HBV
20096 HCV 10903 HCC 11175 Basic 11110
O-143
O-217
LBO-12
O-47
HCV 10273 HCC 10069 Basic 11281
O-144
O-218
O-48
HCC 10578 Basic 11178
O-145
O-219
HCV 10084
O-49 HCC 10011
O-146 Drug 10792
HCC
20002 HCV 11031
LBO-13O-50 HCC 10406
O-271
O-147 Drug 10679
HCC
20131 HCV 10827
LBO-14O-51 HCC 10279
O-272
O-148 Drug 11250
HCC
20132 HCV 10547
O-273
LBO-15
O-52
HCC
20052 HCV 11098 HCC 10252 Drug 20009
LBO-36
O-149
LBO-16
O-53
HCC
20075 HCV 10355 HCC 10258 HBV 20062 AC
LBO-30
O-150
LBO-17
O-54
LF
HCC
20142 HCV 11260 HCC 10513 HBV 20053
LBO-31 WS
O-151
LBO-22
O-55
Cirrhosis 20001 HCV 10910 HCC 11244 HCC 20067
LBO-32
O-152
LBO-18
O-56
Cirrhosis 20144 HCV 10194 HCC 11253 HCC 20137
LBO-33
O-153
LBO-19O-57
HCV 10206 HCC 10648 HCC 20017
LBO-34
O-154
O-58
HCV 10073 HCC 11149 ALF 20113
LBO-35
O-155
O-59
HCV 10834 HCC 11126
O-156
O-60
HBV

Poster Viewing

07:40 07:45 07:50 07:55 08:00 08:05 08:10 08:15 08:20 08:25 08:30 08:35 08:40 08:45 08:45 08:50 08:55 09:00 09:05 09:10 09:15 09:20 09:25 09:30 09:35 09:40 09:45 09:50 09:55 10:00 10:05 10:10 10:15 10:20 10:25 10:30 10:35 10:40 10:45 10:50 10:55 11:00 11:05 11:10 11:15 11:20 11:25 11:30 11:35 11:40 11:45 11:50 11:55 -Room 1BC

17:40 - 19:00

Toward Revision of APASL HCC Guideline
Masao Omata, Pei-Jer Chen, Ryosuke Tateishi, Shuuichiro
Shiina, Jidong Jia, Yoghesh K. Chawla, Wasim Jafri, Cosmas
Lesmana, Laurentius A. Lesmana, Rino A. Gani, ShuntaroObi, Masatoshi Kudo, Norihiro Kokudo, Ogasawara, KwangHyub Han, A. K. Dokmeci, Shiv K. Sarin, Ann-Lii Cheng

Morning Symposium (BMS)

Morning Symposium (Otsuka
Pharmaceutical Co., Ltd.)

Symposium 9 (Moderators: D. Payawal, C.M. Kim, J. Nyu, T. Takayama)
Current Situation of HCC and ICC in Asian PacificS9-1. Surveillance of HCC
Diana A. Payawal

Symposium 10 (Moderators: T. Patel. P.J. Chen,
S. Maeda)
Application of Genom Research for HCC Treatment
S10-1. Genome Research and HCC
Tatsuhiro Shibata

Symposium 11 (Moderators: A.K. Dokmeci,
N. Izumi, S. Shiina)
Update of HCC Treatment
S11-1. Recent Advance in HCC Therapy
Jordi Bruix

S9-2. Nationwide Strategic Action to Control HCC in Korea
Chang-Min Kim
S9-3. Epidemiology and Risk Factors
Man Fung Yuen
S9-4. Surgical Treatment of HCC
Tadatoshi Takayama
S9-5. Surgical Treatment of ICC
Masaru MiyazakiS10-2. Hepatocarcinogenesis in
Mouse Model
Shin Maeda
S10-3. Mechanism of
Chemoprevention
Pei-Jer Chen
S10-4. HCC the Promise of
Immune Therapy
Tushar C. Patel
S10-5. Acyclic Retinoid
Hisataka Moriwaki

Room 4

Basic

Session 7 (Moderators: L. Lesmana,
N. Ormeci, Y. Takei)
Update of NASH/ASH Research
GS7-1. Pathology of NASH
Michiie Sakamoto

Basic

APASL/AASLD
GS7-2. Noninvasive
Joint Meeting Basic
S11-2. Early Diagnosis of(Genetic) Predictor of
PBC and PSC BasicHCC (Biomarker / Imaging)
NASH
Ryosuke Tateishi
Yasuni Nakanuma
Yoshito Ito
Present Situation Basic
GS7-3. Metabolic
S11-3. Recent Advances in Imaging
Diagnosis of Hepatocellular Carcinoma
Disease and NASH
on the Study of Basic
Yasuharu Imai
Kenichi Ikejima
PSC and PBC
S11-4. Biomarker andKieth D. Lidor Basic
GS7-4. DM and
NASH
Imaging Diagnosis of HCC
PBC/GWAS
Basic
Masashi Yoneda
Masatoshi Kudo
Lai Wei
GS7-5. NAFLDRay Kim
S11-5. Local Treatment of HCC Realfed Liver Cirrhosis
Shuichiro Shiina

10191
O-199
10697
O-200
10534
O-201
10266
O-202
10334
O-203
10369
O-204
10495
O-205
10537
O-206

Room 5 Room 6 Room 7 Room 8 2F

HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV
HCV

and HCC
Laurentius A. Lesmana

10228 HCC
O-61
10245 HCC
O-62
11245 HCC
O-63
10734 HCC
O-64
10348 HCC
O-65
10352 HCC
O-66
10937 HCC
O-67
11243 HCC
O-68
11025 HCC
O-69
11341 HCC
O-70

11105 NASH 10544
O-157
O-255
10333 NASH 10975
O-158
O-256
10278 NASH 10898
O-159
O-257
10314 NASH 10806
ICA
O-160
O-258
10093 NASH 10288 (Internatio
O-161
O-259
10483 NASH 10145 nal Club
of
O-162
O-260
10635 NASH 10370 Asscites)
O-163
O-261
11143 NASH 11076
O-164
O-262
10963 NASH 10409
O-165
O-263
10264 NASH 10453
O-166
O-264

11156 HCC
O-71
10582 HCC
O-73
10892 HCC
O-74
10907 HCC
O-75
10326 HCC
O-76
HCC

10144 NASH 10375
O-167
O-265
10460 NASH 11136
ICA
O-168
O-266
10405 NASH 10752 (Internatio
O-169
O-267
10446 NASH 10814 nal Club
of
O-170
O-268
10709 Metabo 10624 Asscites)
O-171
O-269
10789 Metabo 10463
O-172
O-270
Metabo 20037

Coffee BreakLecture 4 (Moderator: D. Crawford)
Future Perspective of Hepatology
Eugene R. Schiff

Okuda Oration (Moderator: M. Omata)Acute on Chronic Liver Failure: APASL ACLF Research Consortium(AARC)- A Proud Asian Initiative
Shiv K. Sarin

Symposium 12 (Moderators: K.H. Han, I. Sakaida,
G. McCaughan) Liver Regeneration
S12-1. Liver Regeneration during Liver Failure
Shiv K. Sarin

Symposium 13 (Moderators: J. Sollano, J. Bruix,
M. Kudo) Recent Trend in HCC Treatment
S13-1. Treatment of Advanced HCC in BCLC B/CTreatment
Massimo Colombo

Session 7 (Moderator: D.J.
Kim, K. Ikejima)
GS7-6. Biomarker and Imagingof NASH （ and Alcohol ）Necati Ormeci

S12-2. Regulation of Liver Progenitor
Cell Responses
Geoffrey McCaughan

S13-2. TACE
Namiki Izumi

GS7-7. Alcoholic Liver
Disease as Systemic Disease
Dong Joon Kim

S12-3. Liver Regeneration for LC
Isao Sakaida

S13-3. Treatment for Sorafenib
Failure / HAIC
Ann-Lii Chen

ALF
ALF
ALF
ALF
ALF

11276
O-225
11218
O-226
11256
O-227
11295
O-228
20104
LBO-37

HCV
HCV
HCV
HCV
HCV

LBO-38Luncheon Symposium (Gilead)

Luncheon Symposium(Bayer)Symposium 14 (Moderators: Y.K. Chawla, A. Thompson, G. Shiha)
Complication of Cirrhosis and the Treatment
S14-1.PVT in Cirrhosis and Non-Cirrhosis Shiv K. Sarin

S14-2. Management of Decompensated HCV Liver Disease
Michael Manns
S14-3. Elastography
Gamal Shiha

Session 8 (Moderators: D. Crawford, R. Gani, E.
Hashimoto)Emerging Trends in NASH
GS8-1. Overview
Etsuko Hashimoto

Session 9 (Moderators: B.C. Sharma, J. Chen,
N. Kawada)
Mechanism of Liver Fibrosis
GS9-1. Complication and Treatment
Shuji Terai

ALF

GS8-2. Emerging Trends inDiagnosis and Evaluation of
NASH
S8-3. Pathological Feature of
NASH
Ian Homer Cua

GS9-2.
Pathogenesis of Fibrosi s
Norifumi Kawada

ALF

ALF

Cirrhosis
Cirrhosis

GS9-3. Biomarker of Fibrosis
Yutaka Inagaki

S14-4. Esophageal Varices
Anuchit Chutaputti

GS8-4. Oxidate Stress and NASH
Keisuke Hino

GS9-4. New Mechanism on
Liver Stellate Cell Activation
Jun ChenS14-5.PHG, GV
Jose Sollano

GS8-5. NASH and FE
Koji Miyanishi

GS9-5. PSC & IVR
Susumu Tazuma

Lecture 5 (Moderator: G. Lau)
Disorders of Iron and Copper in the Asian Pacific Region
Lawrie W. PowellGS8-6. Interactions between Iron,
Fat and Alcohol
Darrell Crawford

Cirrhosis
Cirrhosis
Cirrhosis
Cirrhosis
Cirrhosis
Cirrhosis
Cirrhosis

11060
O-229
11290
O-230
10222
O-231
10092
O-232
10649
O-233
10954
O-234
10897
O-235
10235
O-236
11209
O-237
11089
O-238
11039
O-239
10246
O-240

NASH
NASH
NASH
NASH
NASH

11283
O-251
10946
O-252
11030
O-253
11286
O-254

10957 HCC:T 11112
O-77
O-173
10150 HCC:T 11068
O-78
O-174
HCV 11235 HCC:T 10983
O-79
O-175
HCV 10812 HCC:T 10953
O-80
O-176
HCV 10345 HCC:T 11087
O-81
O-177
HCV 11055 HCC:T 10254
O-82
O-178
Cholan 10240 ERCP 10247
O-179
O-279
Cholan 10374 ERCP 11035
O-180
O-280
Cholan 10403 Gall
10624
O-181
O-281
Cholan 10645 Hema 11085
O-182
O-282
Cholan 11198 Hema 10687
O-183
O-283
Cholan 10469 Hema 10230
O-184
O-284

Poster Viewing

07:40 - 07:45
07:45 - 07:50
07:50 - 07:55
07:55 - 08:00
08:00 - 08:05
08:05 - 08:10
08:10 - 08:15
08:15 - 08:20
08:20 - 08:25
08:25 - 08:30
08:30 - 08:35
08:35 - 08:40
08:40 - 08:45
08:45 - 08:50
08:50 - 08:55
08:55 - 09:00
09:00 - 09:05
09:05 - 09:10
09:10 - 09:15
09:15 - 09:20
09:20 - 09:25
09:25 - 09:30
09:30 - 09:35
09:35 - 09:40
09:40 - 09:45
09:45 - 09:50
09:50 - 09:55
09:55 - 10:00
10:00 - 10:05
10:05 - 10:10
10:10 - 10:15
10:15 - 10:20
10:20 - 10:25
10:25 - 10:30
10:30 - 10:35
10:35 - 10:40
10:40 - 10:45
10:45 - 10:50
10:50 - 10:55
10:55 - 11:00
11:00 - 11:05
11:05 - 11:10
11:10 - 11:15
11:15 - 11:20
11:20 - 11:25
11:25 - 11:30
11:30 - 11:35
11:35 - 11:40
11:40 - 11:45
11:45 - 11:50
11:50 - 11:55
11:55 - 12:00
12:00 - 12:05
12:05 - 12:10
12:10 - 12:15
12:15 - 12:20
12:20 - 12:25
12:25 - 12:30
12:30 - 12:35
12:35 - 12:40
12:40 - 12:45
12:45 - 12:50
12:50 - 12:55
12:55 - 13:00
13:00 - 13:05
13:05 - 13:10
13:10 - 13:15
13:15 - 13:20
13:20 - 13:25
13:25 - 13:30
13:30 - 13:35
13:35 - 13:40
13:40 - 13:45
13:45 - 13:50
13:50 - 13:55
13:55 - 14:00
14:00 - 14:05
14:05 - 14:10
14:10 - 14:15
14:15 - 14:20
14:20 - 14:25
14:25 - 14:30
14:30 - 14:35
14:35 - 14:40
14:40 - 14:45
14:45 - 14:50
14:50 - 14:55
14:55 - 15:00
15:00 - 15:05
15:05 - 15:10
15:10 - 15:15
15:15 - 15:20
15:20 - 15:25
15:25 - 15:30
15:30 - 15:35
15:35 - 15:40
15:40 - 15:45
15:45 - 15:50
15:50 - 15:55
15:55 - 16:00
16:00 - 16:05
16:05 - 16:10
16:10 - 16:15
16:15 - 16:20
16:20 - 16:25
16:25 - 16:30
16:30 - 16:35
16:35 - 16:40
16:40 - 16:45
16:45 - 16:50
16:50 - 16:55
16:55 - 17:00
17:00 - 17:05
17:05 - 17:10
17:10 - 17:15
17:15 - 17:20
17:20 - 17:25
17:25 - 17:30

2016/2/23 Tuesday <HCC/NASH Day>
Room 1A
Room 1D
Room 2 Room 3

HCV
HCV

20085
LBO-20

CEVHAP

Coffee Break

Critical Care in Hepatology
a. Managing Septic Shock in Cirrhosisb. Nutrition in Critically Sick Cirrhoticc. Pathogenesis and Management of HE in Cirrhosis

Session 10 (Moderator: J. George, I.H. Cua, T.
Saibara)Current Management of NASH
GS9-1. Treatment of NASH Based on Metabolic Synd
Toshiji Saibara

Symposium 15 (Moderators: Y.Y. Dan, S. Gupta, M.
Honda) Cancer Stem Cell
S15-1. Potential of Liver Stem Cells for Cirrhotic
Patients
Yock Young Dan

Cirrhosis

GS10-2. NASH and General
Management
Hitoshi Yoshiji

S15-2. Liver Cancer Stem Cells
and MicroRNA
Tetsuhiro Chiba
S15-3. Cancer Stem Cells in
Hepatocellular Carcinoma
Taro Yamashita

Cirrhosis

GS10-3. Management of NASH
Jacob George
GS10-4. Guideline of NASH in
Asia and Europe
Rino R. Gani

*The Program is subject to change

Cirrhosis

Cirrhosis
Cirrhosis
Cirrhosis
Cirrhosis

S15-4. Cancer Stem Cells
Sanjeev Gupta

Cirrhosis
Cirrhosis

S15-5. IPS and Liver Bud
Hideki Taniguchi

Failure

10541
O-241
10249
O-242
10640
O-243
10884
O-244
11020
O-245
10671
O-246
10024
O-247
10421
O-248
10621
O-249
11194
O-250

Poster Session
Culture Night 19:30-21:30

HCC
APASL/EASL Joint Meeting
Non-Invasive Diagnosis of
Fibrosis: EASL Clinical Practice
Guidelines and Future
Directions(Laurent Castera)
Autoimmune Liver Disease:
EASL Clinical Practice
Guidelines and Future
Directions(Tom Hemming Karlsen)
Non-Invasive Diagnosis of
Fibrosis: APASL Clinical
Practice Guidelines and Future
Directions(Hiroshi Yatsuhashi)
AIH(Atsushi Tanaka)

HCC
HCC
HCC
HCC
HCC
HCC
HCC
HCC
HCC

10244
O-131
11177
O-132
10526
O-133
10408
O-134
10187
O-135
10855
O-136
10256
O-137
11083
O-138
11092
O-139
11095
O-140

Tumors 10034 E

O-185
Tumors 10833 E

O-186
Surgery 10441 E
O-187
Surgery 10761 Viral
O-188
Surgery 10987 Viral
O-189
Other 10091 Viral
O-285
Other 10186 Viral
O-286
Other 10936
O-287
Other

20165
LBO-

11320
O-220
10617
O-221
20040
LBO-39

10402
O-222
10486
O-223
11216
O-224
20094
LBO-40

CEVHAP

2016/2/24 Wednesday < WHO/Civil Day >Room 1BC
07:30 - 07:35
07:35 - 07:40
07:40 - 07:45
07:45 - 07:50
07:50 - 07:55
07:55 - 08:00
08:00 - 08:05
08:05 - 08:10
08:10 - 08:15
08:15 - 08:20
08:20 - 08:25
08:25 - 08:30
08:30 - 08:35
08:35 - 08:40
08:40 - 08:45
08:45 - 08:50
08:45 - 08:50
08:50 - 08:55
08:55 - 09:00
09:00 - 09:05
09:05 - 09:10
09:10 - 09:15
09:15 - 09:20
09:20 - 09:25
09:25 - 09:30
09:30 - 09:35
09:35 - 09:40
09:40 - 09:45
09:45 - 09:50
09:50 - 09:55
09:55 - 10:00
10:00 - 10:05
10:05 - 10:10
10:10 - 10:15
10:15 - 10:20
10:20 - 10:25
10:25 - 10:30
10:30 - 10:35
10:35 - 10:40
10:40 - 10:45
10:45 - 10:50
10:50 - 10:55
10:55 - 11:00
11:00 - 11:05
11:05 - 11:10
11:10 - 11:15
11:15 - 11:20
11:20 - 11:25
11:25 - 11:30
11:30 - 11:35
11:35 - 11:40
11:40 - 11:45
11:45 - 11:50
11:50 - 11:55
11:55 - 12:00
12:00 - 12:05
12:05 - 12:10
12:10 - 12:15
12:15 - 12:20
12:20 - 12:25
12:25 - 12:30
12:30 - 12:35
12:35 - 12:40

Room 1A
APASL General Business Meeting

CEV-HAP Symposium

Coffee BreakWHO Symposium

Closing Ceremony*The program is subject to change.

Open Lecture for Citizens(in Japanese)
HCV
Fumio Imazeki
HBV
Yoshiyuki Ueno
NASH
Etsuko Hashimoto
HCC
Ryosuke Tateishi